Scientists have successfully treated monkeys several days after the animals were infected with Sudan ebolavirus (SUDV). The study is important, according to the researchers, because no proven treatments against SUDV exist and little is known about the window of opportunity for treating the infection.
The research was funded by the National Institutes of Health (NIH). Scientists identified SUDV and Zaire ebolavirus (EBOV) in 1976, but EBOV has been the more common cause of outbreaks and has been the focus of nearly all treatment and vaccine research. When an EBOV variant swept through West Africa in 2014-15, physicians treated patients with several experimental therapies but it is unknown whether any of those products would be effective against SUDV.
The research was funded by the National Institutes of Health (NIH). Scientists identified SUDV and Zaire ebolavirus (EBOV) in 1976, but EBOV has been the more common cause of outbreaks and has been the focus of nearly all treatment and vaccine research. When an EBOV variant swept through West Africa in 2014-15, physicians treated patients with several experimental therapies but it is unknown whether any of those products would be effective against SUDV.
With that need in mind, scientists at the University of Texas Medical Branch (UTMB) tested a new antiviral drug delivered intravenously to rhesus macaques using a lipid nanoparticle platform (LNP) developed by Arbutus Biopharma, based in British Columbia. The RNA-based therapeutic, called a "small-interfering RNA (siRNA)," can target specific genes to prevent viruses from replicating and may offer advantages compared to other medical countermeasures. The LNP delivery system encapsulates the drug, can increase its potency, and allows the bloodstream to deliver the drug to targeted tissues.
‘No proven treatments against Sudan ebolavirus (SUDV) exist and little is known about the window of opportunity for treating the infection.’
The researchers are continuing their investigation of siRNA-LNP therapeutics to determine whether the approach could be effective against additional types of Ebola viruses and other hemorrhagic fever viruses.
Source: Eurekalert
- << Genes Regulated by the Protein Foxn1 Identified
- Obesity Is a Stand-Alone High-Risk Factor for Heart Failure >>
Recommended Reading
Link Between Ebola Survival and Co-Infection With Malaria Parasites
People infected with Ebola virus were 20% more likely to survive if they were co-infected with malaria-causing Plasmodium parasites.
The Scripps Research Institute Scientists Pinpoint Ebola's Weak Spots
Scientists are harnessing an imaging technique called cryo-electron microscopy to create high-resolution, 3-D images of Ebola virus and the antibodies that fight it.
Sierra Leone Stops Mandatory Testing of Corpses for the Ebola Virus
Sierra Leone declared that it would stop the mandatory testing of all dead bodies for the Ebola virus.
